Psykofarmakologisk behandling af angst
DOI:
https://doi.org/10.7146/pl.v14i1.135790Abstract
The clinical and theoretical rationale of psychopharmalogical treatment of anxiety disorders is reviewed from the viewpoint of neuropsychiatry. It is underlined that anxiety in clinical settings is a broad concept, and that a rigorous differential diagnostic
process according to DSM-III or ICD-10 classification systems is mandatory for rational pharmacotherapy. Recent investigations of the pharmacodynamics of anxiolytic psychotropic drugs has focused on neurotransmitter enzymes and receptors. The delineation of different families of serotonin and dopamin receptors represents important progress in the development of drugs with greater clinical efficacy and more favourable side effects. The importance of combining psychopharmacological treatment
and psychotherapy is discussed.
Downloads
Published
How to Cite
Issue
Section
License
Ophavsret er tidsskriftets og forfatternes. Det er gældende praksis, at artikler publiceret i Psyke & Logos, som efterfølgende oversættes til andet sprog, af forfatteren frit kan publiceres i internationale tidsskrifter, dog således at det ved reference fremgår, at den oversatte artikel har et forlæg i en dansksproget version i Psyke & Logos. Artikler kan frit deles og linkes til på forsknings- og undervisningsnetværk (så som Blackboard). Link foretrækkes, fordi det giver oplysning om brug af tidsskriftets artikler.
